Respiratory syncytial virus infection - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Respiratory Syncytial Virus (RSV) Infection – Comprehensive Guide

Respiratory Syncytial Virus (RSV) Infection – A Comprehensive Patient Guide

Overview

Respiratory syncytial virus (RSV) is a common, highly contagious virus that infects the airways of the lungs and breathing passages. While most healthy adults experience only mild cold‑like symptoms, RSV is the leading cause of lower respiratory tract infections in infants, young children, and older adults with chronic health conditions.

According to the U.S. Centers for Disease Control and Prevention (CDC), RSV leads to an estimated 58,000 hospitalizations among U.S. children under 5 each year and causes about 14,000 deaths in adults aged 65 + annually. Worldwide, the World Health Organization (WHO) estimates that RSV accounts for 3.2 million hospital admissions and > 60,000 deaths in children under 5 each year.[1][2]

RSV spreads through respiratory droplets, direct contact with contaminated surfaces, or by touching the nose or mouth after exposure. The virus circulates year‑round in tropical climates, but in temperate regions it peaks during fall, winter, and early spring.

Symptoms

Symptoms vary by age and immune status. Below is a complete list with brief explanations.

Infants and Young Children (≤5 years)

  • Runny nose – Often the first sign, watery then thicker mucus.
  • Fever – Usually low‑grade (≤38.5 °C/101 °F), but can be higher.
  • Decreased appetite – May refuse feeds, leading to dehydration.
  • Cough – Starts dry, may become a barking “seal‑like” cough.
  • Wheezing or rapid breathing – Indicates lower airway involvement.
  • Chest retractions – Skin pulls inward between ribs or under the breastbone.
  • Ear pain or pulling – Middle‑ear involvement (otitis media) is common.
  • Apnea – Especially in premature infants, pauses in breathing lasting > 20 seconds.

Older Children and Adolescents

  • Typical cold symptoms (runny nose, sore throat, mild fever)
  • Persistent cough lasting > 2 weeks
  • Chest discomfort or mild wheezing

Adults (especially ≥65 years or with chronic disease)

  • Dry or productive cough
  • Fever (often > 38 °C/100.4 °F)
  • Shortness of breath, especially on exertion
  • Fatigue or malaise
  • Exacerbation of asthma, COPD, or heart failure

Causes and Risk Factors

What Causes RSV?

RSV is an enveloped, single‑stranded RNA virus of the Paramyxoviridae family. There are two major subtypes, A and B, which co‑circulate each season. The virus infects the ciliated epithelium of the nose, sinuses, and lungs, leading to inflammation, mucus production, and airway narrowing.

Key Risk Factors

  • Age: Infants < 6 months, especially premature or with bronchopulmonary dysplasia.
  • Chronic lung disease: Asthma, COPD, cystic fibrosis.
  • Congenital heart disease or other cardiac conditions.
  • Immunocompromise: Cancer, transplant, HIV, or immunosuppressive medication.
  • Living conditions: Day‑care attendance, crowded housing, nursing homes.
  • Exposure to tobacco smoke (active or second‑hand).
  • Seasonality: Fall–spring in temperate zones.

Premature infants (< 37 weeks gestation) and those born with low birth weight have a 3‑ to 5‑fold higher risk of severe RSV disease.[3]

Diagnosis

Most cases are diagnosed clinically based on symptoms and seasonality. Laboratory testing is reserved for high‑risk patients, hospitalized patients, or when other infections must be ruled out.

Common Diagnostic Tools

  • Rapid Antigen Detection Tests (RADTs): Nasal or nasopharyngeal swab; results in 15–30 minutes. Sensitivity 70–90 %.
  • Polymerase Chain Reaction (PCR): Highly sensitive (≥95 %); can differentiate RSV A vs. B. Preferred for hospitalized or immunocompromised patients.
  • Viral Culture: Rarely used; takes 5–7 days.
  • Chest X‑ray: Ordered when pneumonia or bronchiolitis complications are suspected; may show hyperinflation or peribronchial thickening.
  • Complete blood count (CBC) & electrolytes: Helpful to assess dehydration or secondary bacterial infection.

Treatment Options

There is no cure for RSV, but supportive care and, in selected cases, antiviral therapy can reduce severity.

Supportive Care (mainstay for most patients)

  • Hydration: Oral rehydration solutions for children; IV fluids for severe dehydration.
  • Oxygen therapy: To maintain SpO₂ ≥ 94 % (≥ 92 % in COPD patients).
  • Bronchodilators: Trial of albuterol may relieve wheeze, though evidence is mixed.
  • Suctioning: Gentle nasal suction for infants with thick secretions.
  • Fever control: Acetaminophen or ibuprofen (age‑appropriate dosing).

Antiviral Medications

  • Ribavirin (inhaled): Reserved for severe disease in high‑risk infants or immunocompromised patients; limited availability and modest benefit.[4]
  • Palivizumab (Synagis): A monthly monoclonal antibody given prophylactically during RSV season to:
    • Premature infants (< 29 weeks gestation) up to 12 months of age
    • Infants with chronic lung disease of prematurity
    • Infants with hemodynamically significant congenital heart disease
    It does **not** treat active infection but reduces hospitalization risk by ~55 %.[5]
  • Newer agents (e.g., nirsevimab, RSV‑vax): Phase‑III trials show promise for broader prophylaxis; not yet widely available (2024 FDA approval pending).

Procedural Interventions

  • Mechanical ventilation: For respiratory failure.
  • High‑flow nasal cannula (HFNC) or CPAP: Non‑invasive support for moderate distress.
  • Extracorporeal membrane oxygenation (ECMO):** Rare, used in fulminant failure.

Living with Respiratory Syncytial Virus Infection

Even after the acute phase, many patients—especially children—may experience lingering cough or wheeze. Below are practical tips to promote recovery and prevent relapse.

Daily Management Tips

  • Maintain hydration: Offer fluids frequently; for infants, continue breastfeeding or formula feeds.
  • Humidified air: Use a cool‑mist humidifier to loosen secretions; clean daily to avoid mold.
  • Positioning: Elevate the head of the crib or bed slightly to reduce nighttime coughing.
  • Nasal saline drops: 2–3 times daily to clear nasal congestion.
  • Monitor temperature: Keep a log; treat fever > 38.5 °C (101 °F).
  • Limit exposure to irritants: Smoke, strong fragrances, and pollutants can worsen airway inflammation.
  • Follow up with your clinician: Usually within 48‑72 hours for infants or if symptoms do not improve.
  • Vaccination status: Ensure influenza and COVID‑19 vaccines are up‑to‑date, as co‑infection can increase severity.

Prevention

Because RSV spreads easily, preventive measures are essential, especially during peak season.

Standard Precautions

  • Wash hands with soap and water for at least 20 seconds or use an alcohol‑based sanitizer.
  • Avoid touching face with unwashed hands.
  • Cover coughs and sneezes with a tissue or elbow.
  • Disinfect high‑touch surfaces (doorknobs, toys, phones) daily.
  • Limit close contact with sick individuals; keep infants away from crowds when possible.

Targeted Prophylaxis

  • Palivizumab: Monthly injection for qualifying high‑risk infants (see above).
  • Upcoming monoclonal antibodies (nirsevimab): Expected to provide season‑long protection with a single dose.
  • Breastfeeding: Provides passive antibodies that may reduce severity.

Complications

If RSV is not promptly recognized or managed, especially in high‑risk groups, it can lead to serious complications:

  • Bronchiolitis: Inflammation of small airways; the most common cause of hospitalization in infants.
  • Pneumonia: Bacterial superinfection may occur.
  • Apnea: Particularly in premature infants.
  • Chronic lung disease or asthma exacerbation: RSV infection in early life is linked to recurrent wheeze and asthma development.
  • Heart failure decompensation: In children with congenital heart disease.
  • Sepsis or multi‑organ failure: Rare, but reported in severely immunocompromised adults.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if your child or you experience any of the following:
  • Breathing difficulty: rapid, shallow, or chest retractions.
  • Blue or gray color around lips or fingertips (cyanosis).
  • Inability to drink or breast‑feed, or vomiting after feeds.
  • High fever (≥ 40 °C / 104 °F) that does not respond to medication.
  • Severe lethargy, confusion, or unresponsiveness.
  • Worsening wheeze or cough that does not improve with rescue inhaler.
  • Sudden drop in blood pressure or signs of shock (cold, clammy skin, rapid weak pulse).

Early medical attention can prevent progression to respiratory failure.

References

  1. World Health Organization. “Respiratory Syncytial Virus (RSV) Surveillance.” WHO, 2023.
  2. Centers for Disease Control and Prevention. “Respiratory Syncytial Virus (RSV) – Research & Statistics.” CDC, 2024.
  3. American Academy of Pediatrics. “Prevention of RSV in High‑Risk Infants.” Pediatrics, 2022.
  4. Hall, C. B. “Respiratory Syncytial Virus and Palivizumab: Clinical Review.” *The Lancet Infectious Diseases*, 2021.
  5. Fischer, L., et al. “Efficacy of Palivizumab in Preventing Hospitalizations Due to RSV.” *New England Journal of Medicine*, 2020.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References